This brand name is authorized in United States
The drug ZULRESSO contains one active pharmaceutical ingredient (API):
|
1
Brexanolone
UNII S39XZ5QV8Y - BREXANOLONE
|
|
Brexanolone is indicated for the treatment of postpartum depression (PPD) in adults. The mechanism of action is not fully understood, but is thought to be related to its positive allosteric modulation of GABAA receptors. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| ZULRESSO Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: US | FDA, National Drug Code | Identifier(s): 72152-547 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
